The FDA has granted orphan drug designation to Acucela's drug candidate emixustat hydrochloride (emixustat) for the treatment of Stargardt disease. The company is aiming to launch a proof-of-concept trial in 2018. We are very pleased to ... American Academy of Ophthalmology, 1 week ago
Emixustat from Acucela granted orphan drug designation for Stargardt disease - Healio, 1 week ago
Stargardt Disease Drug Candidate Receives Orphan Drug Status - Monthly Prescribing Reference, 1 week ago
BRIEF-Kubota Pharmaceutical Holdings unit gets orphan drug designation from FDA for treatment of stargardt disease
n"Jan 6 Kubota Pharmaceutical Holdings Co Ltd : * Says its unit Acucela Inc announced that the FDA (U.S. Food and Drug Administration) granted orphan drug designation to Acucela's leading drug candidate emixustat hydrochloride("emixustat") for the ...Reuters UK, 1 week ago Acucela Receives Orphan Drug Designation from the FDA for the Treatment of Stargardt Disease 4 Traders, 1 week ago
on your WebpageAdd Widget >Get your members hooked!